Edwards Lifesciences Corporation : A well-established uptrend
Entry price | Target | Stop-loss | Potential |
---|
US$120.28 |
US$0 |
US$114.9 |
-100% |
---|
Edwards Lifesciences is trading in a bullish trend and several arguments are in favor of the continuation of this trend.
From a fundamental viewpoint, the medical device company is strong. It reported recently third quarter results that beat Wall Street expectations. The Thomson Reuters consensus revised regularly upward EPS estimates of the company for the current year to USD 7.17.
Technical patterns are in the green: prices are up for several months. A bullish gap has recently arisen. The movement should continue in the coming trading sessions. Indeed, the 20-day moving average upward oriented should help to reach new highest levels toward the USD 133.
In consequence, investors can take a long position in Edwards Lifesciences with a first target at USD 132.90. However, a stop loss will be set under the recent gap at USD 114.9.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.